The study evaluated the association of interleukin-2 (IL2) receptor (R) levels in the blood (a protein present on immune cells) in selecting a treatment for advanced-stage follicular lymphoma with a low tumor burden (FL-LTB). The study showed that patients with high IL-2R levels had better survival when treated with rituximab (Rituxan) in combination with chemotherapy compared to rituximab alone.

This study compared acalabrutinib (Calquence) and ibrutinib (Imbruvica) for the treatment of patients with chronic lymphocytic leukemia (CLL). The data showed that both drugs had similar effectiveness while acalabrutinib showed fewer cardiovascular side effects compared to ibrutinib.

This study investigated the effectiveness and safety of bevacizumab (Avastin) administered either on the same day or a few days before chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC). The data showed that bevacizumab administered 4 days before chemotherapy significantly improved overall survival with fewer side effects than on the same day.

This study reported the effectiveness and safety of longer rituximab (Rituxan) maintenance therapy schedules (more than 2 years) for the treatment of patients with relapsed or refractory (r/r) indolent (painless) non-Hodgkin lymphoma (iNHL). The data showed that maintenance for up to 2 years with rituximab after response to initial induction remains the standard of care in patients with r/r iNHL.

This study investigated the effectiveness and safety of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR) T-cell therapy for patients with previously treated relapsed or refractory (r/r) multiple myeloma (MM). The data showed that a single dose of cilta-cel was safe and effective for the treatment of these patients.

This study compared the safety and effectiveness between eribulin (Halaven) and non-eribulin-based chemotherapy regimens in patients with advanced breast cancer (BC). The data showed that eribulin significantly improved survival outcomes with manageable side effects in these patients.

This review looked at whether a vegan diet can improve type 2 diabetes (T2D). It found that a vegan diet can lower glucose (sugar) levels for people with T2D.

This study looked at the safety and effectiveness of olokizumab (Artlegia) as an add-on to methotrexate (Otrexup) treatment in rheumatoid arthritis. It found the olokizumab was associated with significant improvements in RA symptoms and physical function.

This study looked at the effectiveness of deep brain stimulation (DBS) in patients with Parkinson's disease (PD) and stomach problems. It found that DBS was associated with an improvement in stomach disorders and a reduced need for medication.

This study looked at the use of aflibercept (Eylea) eye injections for the treatment of severe nonproliferative diabetic retinopathy (DR; diabetic eye disease). It found that more than half of the patients treated with aflibercept showed a significant improvement in DR after 6 months.